Abstract Search

ba0003OP8 | Clinical | ECTS2014

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

Appelman-Dijkstra Natasha , Claessen Kim , Hamdy Neveen , Pereira Alberto , Biermasz Nienke

see PP404....

0 shares

ba0003pp404 | Other diseases of bone and mineral metabolism | ECTS2014

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

Appelman-Dijkstra Natasha , Claessen Kim , Hamdy Neveen , Pereira Alberto , Biermasz Nienke

Background: Adult GH Deficiency (GHD) is associated with decreased bone mass and increased fracture risk. Recombinant human GH (rhGH) replacement therapy leads to progressive increases in bone mineral density (BMD) for up to 7 years of treatment, but little is known on longer term effects of rhGH therapy on bone mass or fracture risk.Methods: 230 GHD patients (mean age 47.1 years, 52.6% female) on rhGH replacement therapy for ≥5 years were included...

0 shares

Bone Abstracts

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

BiosciAbstracts